EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Ticagrelor versus clopidogrel in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis

Ignacio Gallo, Gloria Heredia, Rafael Gonzalez-Manzanares, Cristina Urbano, Diana Ladera, Luis Carlos Maestre, Inmaculada Osuna, Francesco Costa, Javier Suarez de Lezo, Francisco Hidalgo, Jorge Perea, Miguel Romero und 2 weitere

Medicina Clínica · 2026-01 · 166 (1) · 107256

DOI: 10.1016/j.medcli.2025.107256 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Medicina Clínica, 2026-01. Verfasst von Ignacio Gallo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Reina Sofía University Hospital, Córdoba, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdo…. Hauptthemen laut MEDLINE: Clopidogrel, Ticagrelor, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: This study aimed to evaluate the efficacy and safety of ticagrelor-based dual antiplatelet therapy (DAPT) compared to clopidogrel-based DAPT in patients with chronic coronary syndrome (CCS) undergoing elective percutaneous coronary intervention (PCI) in a real-world setting. METHODS AND RESULTS: This was a retrospective, single-centre study including consecutive CCS patients discharged on DAPT after elective PCI between 2019 and 2022. Propensity score matching (PSM) was performed to account for confounding factors, including clinical, angiographic, and procedural variables. The primary endpoint was the incidence of major adverse cardiovascular events (MACE) at 1-year follow-up, defined as a composite of all-cause death, non-fatal myocardial infarction, and non-fatal stroke. Secondary endpoints included the individual components of MACE and major bleeding, A total of 1236 patients were included, 731 treated with ticagrelor and 505 with clopidogrel. Before matching, ticagrelor prescription was associated with higher thrombotic risk and lower bleeding risk profile. PSM resulted in 351 pairs. Ticagrelor was associated with a lower 1-year incidence of MACE (2.3% vs. 6.6%; HR 0.34, 95% CI 0.15-0.76; p=0.008) and all-cause mortality (2.3% vs. 5.1%; HR 0.43, 95% CI 0.19-0.99; p=0.049). No significant differences were observed in non-fatal myocardial infarction, non-fatal stroke, or major bleeding. CONCLUSION: In this cohort of patients with CCS undergoing PCI, ticagrelor was associated with a lower incidence of MACE at 1-year follow-up compared to clopidogrel, without an increase in major bleeding. Dedicated randomised controlled trials are needed to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelTicagrelorPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsHumansPropensity ScoreMaleRetrospective StudiesFemaleAgedMiddle AgedStrokeHemorrhageMyocardial InfarctionTreatment OutcomeDual Anti-Platelet TherapyChronic Disease

Stichwörter der Autor:innen

Anti-platelet therapiesChronic coronary syndromeClopidogrelCoronary artery diseaseDAPTEnfermedad coronariaIntervencionismo coronario percutaneoPercutaneous coronary interventionsSíndrome coronario crónicoTAPDTerapia antiplaquetariaTicagrelor

Substanzen

ClopidogrelTicagrelorPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Reina Sofía University Hospital, Córdoba, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
  • Department of Cardiology, Reina Sofía University Hospital, Córdoba, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain; CIBER de Enfermedades Cardiovasculares, Instituto de Salud…
  • Department of Medicine, University of Córdoba, Córdoba, Spain.
  • Área del Corazón, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; Hospital Universitario Virgen de la Victoria, Málaga, Spain; Departamento de Medic…

Zitieren

APA

Gallo, I., Heredia, G., Gonzalez-Manzanares, R., Urbano, C., Ladera, D., Carlos Maestre, L., Osuna, I., Costa, F., Suarez de Lezo, J., Hidalgo, F., Perea, J., Romero, M., Pan, M., & Ojeda, S. (2026). Ticagrelor versus clopidogrel in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis. Medicina Clínica, 166(1), 107256. https://doi.org/10.1016/j.medcli.2025.107256

Vancouver

Gallo I, Heredia G, Gonzalez-Manzanares R, Urbano C, Ladera D, Carlos Maestre L, et al. Ticagrelor versus clopidogrel in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis. Medicina Clínica. 2026;166(1):107256. doi:10.1016/j.medcli.2025.107256

BibTeX
@article{Gallo2026,
  author = {Gallo, Ignacio and Heredia, Gloria and Gonzalez-Manzanares, Rafael and Urbano, Cristina and Ladera, Diana and Carlos Maestre, Luis and Osuna, Inmaculada and Costa, Francesco and Suarez de Lezo, Javier and Hidalgo, Francisco and Perea, Jorge and Romero, Miguel and Pan, Manuel and Ojeda, Soledad},
  title = {Ticagrelor versus clopidogrel in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis},
  journal = {Medicina Clínica},
  year = {2026},
  volume = {166},
  number = {1},
  pages = {107256},
  doi = {10.1016/j.medcli.2025.107256}
}
Kostenlos starten →